Publikationen, an denen er mitarbeitet Ángel Ramírez Payer (8)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

2018

  1. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2015

  1. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

  2. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy

    Leukemia and Lymphoma, Vol. 56, Núm. 11, pp. 3096-3102

  3. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial

    Haematologica, Vol. 100, Núm. 9, pp. 1207-1213

2014

  1. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

    Haematologica

  2. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

    Blood, Vol. 123, Núm. 24, pp. 3790-3796

2013

  1. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

    Leukemia, Vol. 27, Núm. 5, pp. 1100-1106